Inclusion Criteria:

1. Any patient with a hematologic or oncologic diagnosis without morphological evidence
of disease in which allogeneic HSCT is thought to be beneficial.

2. Patients must have a related donor who is a two or more allele mismatch at the HLA-A;
B; C; DR loci.

3. Patients must have adequate organ function:

1. LVEF (Left ventricular ejection fraction) of >50%

2. Diffusion Capacity for Carbon Monoxide (DLCO) >50% of predicted corrected for
hemoglobin

3. Adequate liver function as defined by a serum bilirubin <1.8, Aspartate
Aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5X upper limit of
normal

4. Creatinine clearance of > 60 ml/min

4. Performance status > 80% (TJU Karnofsky)

5. Hematopoietic Comorbidity Index (HCT-CI) Score < 5 Points

6. Patients must be willing to use contraception if they have childbearing potential

7. Able to give informed consent, or if decisionally impaired, have a legal next of kin
or guardian that can give informed consent

Exclusion Criteria:

1. Performance status < 80 % (TJU Karnofsky)

2. HCT-CI Score > 5 Points

3. Combination of Performance status of < 80% (TJU Karnofsky) and an HCT-CI of 4 points
or more.

4. HIV positive

5. Active involvement of the central nervous system with malignancy

6. Psychiatric disorder that would preclude patients from signing an informed consent

7. Pregnancy

8. Patients with life expectancy of < 6 months for reasons other than their underlying
hematologic/oncologic disorder

9. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or
who have recently received horse or rabbit anti-thymocyte globulin and have an ATG
level of > 2 ugm/ml

10. Patients who cannot receive cyclophosphamide

11. Patients with evidence of another malignancy, exclusive of a skin cancer that
requires only local treatment, should not be enrolled on this protocol